This course focuses on antimicrobial stewardship as an approach to address healthcare-associated infections (HAI) resulting from multi-drug resistance organisms in acute care settings.
Since the most recent ECDC rapid risk assessment in 2021, the number of EU/EEA countries reporting hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23 has increased from four to ten and the number of cases reported to ECDC by the countries, increased from 12 to 143.
This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
For 2022, 29 European Union/European Economic Area (EU/EEA) countries reported 8 565 confirmed cases of Shiga toxin-producing Escherichia coli (STEC) infection.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7-13 January 2024 and includes updates on SARS-CoV-2, measles, diphtheria, Middle East respiratory syndrome coronavirus (MERS-CoV) and poliomyelitis.
Sixty cases of diphtheria due to toxigenic Corynebacterium diphtheriae (n=29) or C. ulcerans (n=31), and one case with unknown pathogen were reported to ECDC in 2021.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 December 2023 and includes updates on measles, chikungunya, dengue, SARS-CoV-2, diphtheria, West Nile virus, respiratory virus epidemiology and influenza.
Haemophilus influenzae type b (Hib) is an obligate human pathogen and an important cause of invasive bacterial infections in both children and adults, with the highest incidence among young children.
A joint study of the National Public Health Organization in Greece (NPHO) and the European Centre for Disease Prevention and Control (ECDC) conducted in 15 Greek hospitals in 2022 sheds light on the rapid spread of carbapenemase-producing, highly drug-resistant Klebsiella pneumoniae sequence type (ST) 39, following its initial documentation in a European-wide genomic survey in 2019.